Therapeutic potential of nanoparticulate systems for macrophage targeting

被引:200
作者
Chellat, F
Merhi, Y
Moreau, A
Yahia, L
机构
[1] Ecole Polytech, Biomed Engn Inst, Montreal, PQ H3C 3A7, Canada
[2] Univ Montreal, Lab Pathol Expt, Inst Cardiol Montreal, Montreal, PQ H1T 1C8, Canada
[3] Hop St Justine, Ctr Rech, Lab Genet Mol Os & Malformat Squelett, Montreal, PQ H3T 1C5, Canada
基金
加拿大健康研究院;
关键词
review; macrophage targeting; nanoparticles; inflammatory diseases;
D O I
10.1016/j.biomaterials.2005.05.044
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
The use of non-viral nanoparticulate systems for the delivery of therapeutic agents is receiving considerable attention for medical and pharmaceutical applications. This increasing interest results from the fact that these systems can be designed to meet specific physicochemical requirements, and they display low toxic and immunogenic effects. Among potential cellular targets by drug-loaded nanoparticles, macrophages are considered because they play a central role in inflammation and they act as reservoirs for microorganisms that are involved with deadly infectious diseases. The most common and potent drugs used in macrophage-mediated diseases treatment often induce unwanted side effects, when applied as a free form, due to the necessity of high doses to induce a satisfactory effect. This could result in their systemic spreading, a lack of bioavailability at the desired sites, and a short half-life. Therefore, the use of drug-loaded nanoparticles represents a good alternative to avoid, or at least decrease, side effects and increase efficacy. In this manuscript, we present an overview of the usefulness of nanoparticles for macrophage-mediated therapies in particular. We discuss, though not exhaustively, the potential of therapeutic agent-loaded nanoparticles for some macrophage-mediated diseases. We also underline the most important parameters that affect the interaction mechanisms of the macrophages and the physicochemical aspects of the particulate systems that may influence their performance in macrophage-targeted therapies. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:7260 / 7275
页数:16
相关论文
共 181 条
  • [1] INTERACTIONS OF ANTISENSE DNA OLIGONUCLEOTIDE ANALOGS WITH PHOSPHOLIPID-MEMBRANES (LIPOSOMES)
    AKHTAR, S
    BASU, S
    WICKSTROM, E
    JULIANO, RL
    [J]. NUCLEIC ACIDS RESEARCH, 1991, 19 (20) : 5551 - 5559
  • [2] LONG-CIRCULATING (STERICALLY STABILIZED) LIPOSOMES FOR TARGETED DRUG-DELIVERY
    ALLEN, TM
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 1994, 15 (07) : 215 - 220
  • [3] ALVING C R, 1988, Advanced Drug Delivery Reviews, V2, P107, DOI 10.1016/0169-409X(88)90007-5
  • [4] Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, and perspectives
    Andreesen, R
    Hennemann, B
    Krause, SW
    [J]. JOURNAL OF LEUKOCYTE BIOLOGY, 1998, 64 (04) : 419 - 426
  • [5] [Anonymous], 1975, PHAGOCYTIC ENGULFMEN
  • [6] Albumin nanoparticles as carriers for a phosphodiester oligonucleotide
    Arnedo, A
    Espuelas, S
    Irache, JM
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 244 (1-2) : 59 - 72
  • [7] FATE OF MOUSE MACROPHAGES RADIOLABELED WITH PKH-95 AND INJECTED INTRAVENOUSLY
    AUDRAN, R
    COLLET, B
    MOISAN, A
    TOUJAS, L
    [J]. NUCLEAR MEDICINE AND BIOLOGY, 1995, 22 (06): : 817 - 821
  • [8] Expression of a mannose/fucose membrane lectin on human dendritic cells
    Avrameas, A
    McIlroy, D
    Hosmalin, A
    Autran, B
    Debre, P
    Monsigny, M
    Roche, AC
    Midoux, P
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1996, 26 (02) : 394 - 400
  • [9] Balland O, 1996, J ANTIMICROB CHEMOTH, V37, P105, DOI 10.1093/jac/37.1.105
  • [10] The role of macrophages, perivascular cells, and microglial cells in the pathogenesis of experimental autoimmune encephalomyelitis
    Bauer, J
    Huitinga, I
    Zhao, WG
    Lassmann, H
    Hickey, WF
    Dijkstra, CD
    [J]. GLIA, 1995, 15 (04) : 437 - 446